Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study
Article first published online: 22 SEP 2011
© 2011 The Japan Society of Hepatology
Volume 41, Issue 11, pages 1057–1065, November 2011
How to Cite
Hyogo, H., Ikegami, T., Tokushige, K., Hashimoto, E., Inui, K., Matsuzaki, Y., Tokumo, H., Hino, F. and Tazuma, S. (2011), Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatology Research, 41: 1057–1065. doi: 10.1111/j.1872-034X.2011.00849.x
- Issue published online: 27 OCT 2011
- Article first published online: 22 SEP 2011
- Received 12 May 2011; revision 31 May 2011; accepted 5 June 2011.
- hyperlipoproteinemia type IIb;
- non-alcoholic steatohepatitis with dyslipidemia;
Aim: Non-alcoholic fatty liver disease (NAFLD) that encompasses a spectrum of liver disorders characterized by simple steatosis, non-alcoholic steatohepatitis (NASH) through cirrhosis, is becoming an important chronic liver disease in Japan. Currently, there is no proven therapy for NASH. In this study, we assessed the efficacy of statin therapy in NASH patients with dyslipidemia.
Methods: Twenty patients with biopsy-proven NASH with dyslipidemia who agreed to participate in this multicentric prospective study were enrolled. The patients were treated for 12 months with pitavastatin 2 mg/day. Clinical and histological alterations were comparatively evaluated before and after treatment. Standard weight loss counseling was continued during the treatment period. Follow-up liver biopsy was performed in 13 patients.
Results: Twenty-five percent of patients had hyperlipoproteinemia type IIa and 75% had hyperlipoproteinemia type IIb at baseline. The levels of alanine aminotransferase, γ-glutamyl transpeptidase and lipid profiles were significantly improved by the treatment with pitavastatin for 12 months. Especially, these improvements were prominent in NASH patients with hyperlipoproteinemia type IIb. While non-alcoholic fatty liver disease activity score and fibrosis stage did not change significantly in all patients, they did improve in 54% and 42% in individual patients, respectively.
Conclusion: NASH-related metabolic parameters improved with therapy including histology in some patients. However, three of 13 patients had progression of fibrosis during the treatment. Our pilot study demonstrated the efficacy of pitavastatin for the treatment of NASH with dyslipidemia, especially with hyperlipoproteinemia type IIb and controlled trials are needed in the future.